Reviewing Tocagen Inc. (TOCA)’s and BioLineRx Ltd. (NASDAQ:BLRX)’s results

Both Tocagen Inc. (NASDAQ:TOCA) and BioLineRx Ltd. (NASDAQ:BLRX) are Biotechnology companies, competing one another. We will contrast their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tocagen Inc. 18.04M 13.86 40.19M -2.02 0.00
BioLineRx Ltd. N/A 0.00 24.67M -0.23 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Tocagen Inc. and BioLineRx Ltd.

Profitability

Table 2 provides us Tocagen Inc. and BioLineRx Ltd.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Tocagen Inc. -222.78% -71.6% -46.1%
BioLineRx Ltd. 0.00% 0% 0%

Institutional and Insider Ownership

The shares of both Tocagen Inc. and BioLineRx Ltd. are owned by institutional investors at 31% and 36.06% respectively. Insiders owned roughly 7.6% of Tocagen Inc.’s shares. Competitively, 4.39% are BioLineRx Ltd.’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Tocagen Inc. -1.47% 5.39% 3.76% 31.85% 19.68% 24%
BioLineRx Ltd. -2.75% -10.11% -26.06% -29.64% -40.1% -39%

For the past year Tocagen Inc. has 24% stronger performance while BioLineRx Ltd. has -39% weaker performance.

Summary

BioLineRx Ltd. beats Tocagen Inc. on 5 of the 9 factors.

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The companyÂ’s lead product candidate is Toca 511 & Toca FC that is in Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial for patients with recurrent high grade glioma (HGG). It is also developing Toca 511 & Toca FC in a Phase 1b clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, melanoma, and renal. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. Tocagen Inc. was founded in 2007 and is headquartered in San Diego, California.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The companyÂ’s other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome. The company has strategic collaborations with Novartis Pharma AG; Merck; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; Genentech Inc. to investigate the combination of BL-8040 and GenentechÂ’s Atezolizumab in various Phase Ib studies for multiple solid tumor indications and acute myeloid leukemia. BioLineRx Ltd. was founded in 2003 and is headquartered in ModiÂ’in, Israel.